D
Dani P. Bolognesi
Researcher at Duke University
Publications - 263
Citations - 19414
Dani P. Bolognesi is an academic researcher from Duke University. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 65, co-authored 261 publications receiving 19001 citations. Previous affiliations of Dani P. Bolognesi include Max Planck Society & Repligen Corporation.
Papers
More filters
Journal ArticleDOI
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Hiroaki Mitsuya,Kent J. Weinhold,P A Furman,M H St Clair,S N Lehrman,Robert C. Gallo,Dani P. Bolognesi,David Walter Barry,Samuel Broder +8 more
TL;DR: The antiviral effects of a thymidine analogue,3'-azido-3'-deoxythymidine (BW A509U), which, as a triphosphate, inhibits the reverse transcriptase of HTLV-III/LAV, and the in vitro immune functions of normal T cells remain basically intact.
Journal ArticleDOI
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
P A Furman,J A Fyfe,M H St Clair,Kent J. Weinhold,Rideout Janet L,G A Freeman,S N Lehrman,Dani P. Bolognesi,Samuel Broder,Hiroaki Mitsuya +9 more
TL;DR: The results reported here suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate derivative efficiently and selectively binds to the HIV reverse transcriptase.
Journal ArticleDOI
Potent suppression of hiv-1 replication in humans by t-20, a peptide inhibitor of gp41-mediated virus entry
J M Kilby,S Hopkins,T M Venetta,B DiMassimo,Gretchen A. Cloud,Jeannette Y. Lee,L Alldredge,Eric Hunter,D. M. Lambert,Dani P. Bolognesi,T J Matthews,M R Johnson,Martin A. Nowak,George M. Shaw,Michael S. Saag +14 more
TL;DR: Proof-of-concept that viral entry can be successfully blocked in vivo is provided, and short-term administration of T-20 seems safe and provides potent inhibition of HIV replication comparable to anti-retroviral regimens approved at present.
Journal ArticleDOI
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of htlv-iii/lav replication, to patients with aids or aids-related complex
Robert Yarchoan,Kent J. Weinhold,H. Kim Lyerly,Edward P. Gelmann,Robert M. Blum,Gene M. Shearer,Hiroaki Mitsuya,Jerry M. Collins,Charles E. Myers,Raymond W. Klecker,Phillip D. Markham,David T. Durack,S. Nusinoff Lehrman,David W. Barry,Margaret A. Fischl,Robert C. Gallo,Dani P. Bolognesi,Samuel Broder +17 more
TL;DR: 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC).
Journal ArticleDOI
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
Kashi Javaherian,A. J. Langlois,Charlene McDanal,K L Ross,L I Eckler,Cindy L. Jellis,Albert T. Profy,James R. Rusche,Dani P. Bolognesi,Scott D. Putney +9 more
TL;DR: The principal neutralizing determinant of human immunodeficiency virus type 1 (HIV-1) is located in the external envelope protein, gp120, and has been mapped to a 24-amino acid-long sequence (denoted RP135), and deletion of this sequence renders the envelope unable to elicit neutralizing antibodies.